About Taos Therapeutics, Inc.
Our Mission
- Taos Therapeutics is developing Mequi, a pioneering agonist + deterrent combination for Alcohol Use Disorder (AUD) - a disease that kills nearly 178,000 Americans a year, more than opioids and stimulants combined.
- Analogous to Suboxone, the gold standard in opioid treatment, Mequi (patent pending) pairs agonist craving control with a hard deterrent in one inseparable pill.
- Three suboptimal, single-mechanism drugs are FDA-approved while 28M adults have AUD and under 3% are treated - a $35B market with payer rails already proven by the opioid playbook.
- We are pursuing the FDA 505(b)(2) pathway, using existing safety data for faster, lower-risk approval.
- Mequi's IP is hard to copy - its two active ingredients are chemically incompatible - opening a clear path to M&A or IPO.